CAR-T cell therapy: Where are we now, and where are we heading?

Abstract

Chimeric antigen receptor (CAR)-T-cell therapies have exhibited remarkable efficacy in the treatment of hematologic malignancies, with 9 CAR-T-cell products currently available. Furthermore, CAR-T cells have shown promising potential for expanding their therapeutic applications to diverse areas, including solid tumors, myocardial fibrosis, and autoimmune and infectious diseases. Despite these advancements, significant challenges pertaining to treatment-related toxic reactions and relapses persist. Consequently, current research efforts are focused on addressing these issues to enhance the safety and efficacy of CAR-T cells and reduce the relapse rate. This article provides a comprehensive overview of the present state of CAR-T-cell therapies, including their achievements, existing challenges, and potential future developments.

• Authors: Jia-Yi Wang, Liang Wang
• Journal: Blood science (Baltimore, Md.) (Blood Sci) Vol. 5 Issue 4 Pg. 237-248 (Oct 2023) ISSN: 2543-6368 [Electronic] United States
• PMID: 37941917 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2023 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the Chinese Medical Association (CMA) and Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College (IHCAMS).